rag-17
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 22, 2023 (NCT05903690)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Superoxide dismutaseANTISENSE INHIBITOR
SOD1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07077668 | Early Phase 1 (Phase 1) | Jul 31, 2025 | Capital Medical University |
| NCT06556394 | Phase 1 | Aug 31, 2024 | Ractigen Therapeutics. |
| NCT05903690 | Early Phase 1 (Phase 1) | May 22, 2023 | Capital Medical University, Ractigen Therapeutics. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Ractigen Therapeutics. | For profit | 2 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1